Type II Diabetes. Diabetes mellitus due to underlying condition
Conditions
Interventions
Intervention 1: Intervention group: menaquinone supplement (in the form of MK-7), will be taken at a single daily dose of 200 microgram along with the main meal for a period of three months.The pure m
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 55 Years
Inclusion criteria
Inclusion criteria: Men and non-postmenopausal women, With type 2 diabetes (at least from 6 months prior to the study), With desire to participate in the study, Age of 20-55 years, BMI 27-35 kg/m2, Who use anti diabetic drugs.
Exclusion criteria
Exclusion criteria: Pregnancy, lactation, menopause, hormone therapy, use of vitamin K containing contraceptives, polycystic ovary syndrome; Presence of diseases affecting vascular calcification or cardiac dysfunction; History of bone, rheumatoid arthritis, thyroid, parathyroid, liver, kidney, intestine disease or malignancies; Presence of infectious or inflammatory disease symptoms or recent surgery; Use of insulin, corticosteroids and anticoagulant drugs such as warfarin and coumarin; Adherence to a specific diet and consumption of any dietary supplements or weight reducing drugs for 3 month prior to the study; Smoking.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood levels of fasting glucose. Timepoint: Before and after the intervention. Method of measurement: Enzymatic method.;Blood levels of fasting insulin. Timepoint: Before and after the intervention. Method of measurement: ELIZA KIT.;Serum levels of HbA1c. Timepoint: Before and after the intervention. Method of measurement: Spectrophotometry.;Insulin resistance index. Timepoint: Before and after the intervention. Method of measurement: Formula.;Blood levels of triglycerides. Timepoint: Before and after the intervention. Method of measurement: Enzymatic method.;Blood levels of total cholestrol. Timepoint: Before and after the intervention. Method of measurement: Enzymatic method.;Blood levels of HDL-cholestrol. Timepoint: Before and after the intervention. Method of measurement: Enzymatic method.;Blood levels of LDL-cholestrol. Timepoint: Before and after the intervention. Method of measurement: Friedewald formula.;Anthropometric indices. Timepoint: Before and after the intervention. Method of measurement: Scale, Stadiometer,Tape.;Body composition indices. Timepoint: Before and after the intervention. Method of measurement: Impedance bio-electric system.;Serum levels of TNF-a. Timepoint: Before and after the intervention. Method of measurement: ELIZA KIT.;Serum levels of hsCRP. Timepoint: Before and after the intervention. Method of measurement: ELIZA KIT.;Serum levels of IL-6. Timepoint: Before and after the intervention. Method of measurement: ELIZA KIT.;Blood levels of dpucMGP. Timepoint: Before and after the intervention. Method of measurement: ELIZA KIT.;Blood levels of PIVKAII. Timepoint: Before and after the intervention. Method of measurement: ELIZA KIT. | — |
Secondary
| Measure | Time frame |
|---|---|
| Dietary intake. Timepoint: Before and after the intervention. Method of measurement: Three day food record questionnaire.;Physical activity level. Timepoint: Before and after the intervention. Method of measurement: IPAQ questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Bahram Pourghassem Gargari
Tabriz University of Medical Sciences
Outcome results
None listed